Skip to content
Buy This GLP
← Research
Evidence

What Swedish Primary Care Physicians Reported About GLP-1 Access

In an October 2024 survey, responding physicians cited limited supply and patient copayments as prescribing barriers.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
Swedish primary care survey, October 2024agree they are effective98%expect them to matter91%cite supply shortages86%cite patient costs69%163 responses analyzed. Response rate: 28%.

A survey of primary care physicians in five Swedish regions recorded 190 responses in October 2024 [1]. Separate research on barriers to getting a GLP-1 prescription considers what can prevent patients from starting. This survey asked physicians what made prescribing difficult at the time.

What the physicians reported

The final sample of 163 respondents excludes incomplete or ineligible replies. Ninety-eight percent agreed that GLP-1 drugs were effective for treating obesity, and 91% expected them to be important in future care [1]. Low availability was cited by 86%, and high patient copayments by 69%. These percentages describe the surveyed physicians’ responses. They do not show how often patients were denied prescriptions.

What the results can tell patients today

The survey response rate was 28%. Since GLP-1 insurance coverage in the United States depends on the plan and indication, the Swedish cost figures do not predict a US copayment. The availability finding describes October 2024, when the authors reported supply shortages. Physicians who chose to respond may have differed from those who did not.

Frequently asked

What barriers did physicians report?
Eighty-six percent cited limited drug availability and 69% cited high patient copayments. The survey was conducted in October 2024.
How many replies were analyzed?
The survey received 190 replies, a 28% response rate. Researchers analyzed 163 responses.
Does this show how many patients were denied?
The survey measured physicians’ reported barriers. It did not count denied prescriptions or observe patient outcomes.

Sources

  1. [1] Sundell I, Wettermark B, Sundström A, Martinell M, Ericsson B (2026). Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey BMC Primary Care. PMID 42557543

Where to get it

GLP-1 telehealth prescribers

The sellers whose own pricing describes an ongoing prescribed plan, rather than a checkout that assumes you already have a script.

See the board →

More in Evidence